Breakthrough therapy designations could allow Vertex Pharmaceuticals Inc. to rapidly expand Kalydeco labeling to cover as much as 60% of the 70,000 worldwide cystic fibrosis population.
The company revealed Jan
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?